

**A PROSPECTIVE STUDY TO EVALUATE
HEMOSTATIC AND METABOLIC PROFILES IN
CHILDHOOD ACUTE LYMPHOBLASTIC
LEUKEMIA RECEIVING L-ASPARAGINASE**

Thesis submitted by:

ABEER IBRAHIM NASR
M.B.,Bch

For partial fulfillment of master degree in pediatrics
Supervised by

Dr. EMAN MONIR SHERIF
Assistant Professor of Pediatrics, Faculty of Medicine,
Ain Shams University

Dr. MANAL M. ABD AL AZIZ
Assistant Professor of Clinical Pathology, Faculty of
Medicine, Ain Shams University

Dr.Ashraf Mahmoud Abd El-Monem
Lecturer of Pediatrics, Faculty of Medicine,
Ain Shams University

Ain Shams University
2006

Acknowledgement

*First and forever, thanks for **ALLAH** helping me to complete this work,*

*I thank gratefully **professor Dr. Eman Monir Sherif**, assistant professor of Pediatrics ,Faculty of Medicine ,Ain Shams University for her kind support and guidance.*

*I am also very grateful to **professor Dr. Manal Mohammed Abd El-Aziz**, assistant professor of Clinical Pathology, ,Faculty of Medicine ,Ain Shams University for her kind supervision and patience reviewing this work,*

*Very special thanks and appreciation to **Dr. Ashraf Mahmoud Abd El-Monem** lecturer of Pediatrics, Faculty of Medicine ,Ain Shams University the person behind all effort and good things in this work and the source for moral and scientific support.*

*Also, I should express my warmest thanks to all **staff members and colleagues** in the Pediatric Oncology Department, Ain Shams University for their kind care and sympathy throughout this work,*

ACKNOWLEDGMENT

List of abbreviations

ALL.....	Acute lymphoblastic leukemia
ALT.....	Alanin transaminase
AML.....	Acute myeloid leukemia
ANLL.....	Acute non lymphoblastic leukemia
AST.....	Aspartate transaminase
BFM.....	Berlin-Frankfort-Munster
C-ALL.....	Common ALL
CCG.....	Children's Cancer Group
CD.....	Cluster of differentiation
CNS.....	Central nervous system
CSF.....	Cerebrospinal fluid
D M.....	Diabetes mellitus
EcA.....	Escherichia coli Asparaginase
EPV.....	Epstein Bar Virus
FAB.....	French-American-British
HIV.....	Human immunodeficiency virus
L-ASP.....	L-asparaginase
MRD.....	Minimal residual disease
PEG-ASP.....	Polyethylene glycol asparaginase
PT.....	Prothrombin time
PTT.....	Partial thromboplastin time
TAT.....	Thrombin anti thrombin
TLC.....	Total leucocytic count
WBC.....	White blood cell

List of tables

Table (1): FAB classification of acute lymphoblastic leukemia	7
Table (2): Non random chromosomal abnormalities in childhood ALL cases.	9
Table (3): Frequency of ploidy groups in childhood ALL cases.	11
Table (4): Clinical and laboratory features at diagnosis in children with ALL.	14
Table (6): Drug interaction with L-asparaginase .	41
Table (6): Age related intrathecal dosage for CNS prophylaxis.	47
Table (7): Age distribution among 30 pediatric ALL patients.	52
Table (8): Sex distribution among 30 pediatric ALL patients.	52
Table (9):Frequency of pretreatment clinical features among 30 pediatric ALL patients.	55
Table(10):Frequency of pretreatment hematological features among 30 pediatric ALL patients.	58
Table (11):Frequency of immunophenotyping among 30 pediatric ALL patients.	60
Table (12)Relation between immunophenotyping and riskstatus.	62
Table (13): Comparison between studied group and control group as regarding age,sex and TAT level.	62
Table (14): Hemostatic changes before, during and after asparaginase therapy.	64

Table (15): Metabolic changes before, during and after asparaginase therapy.	69
Table (16): Relation between TAT level and risk status according to immunophenotyping.	73
Table (17): Correlation between TAT, PT, PTT and fibrinogen levels before asparaginase therapy.	75
Table (18): Correlation between TAT, PT, PTT and fibrinogen levels during asparaginase therapy.	76
Table (19): Correlation between TAT, PT, PTT and fibrinogen levels after asparaginase therapy.	77
Table (20): Clinical feature pre,during and after induction therapy.	78
Table (21): Signs of toxicity according to WHO toxicity grading.	80

List of figures

Figure (1): Age distribution among 30 pediatric ALL patients.	51
Figure (2): Sex distribution among 30 pediatric ALL patients.	53
Figure (3): Frequency of pretreatment clinical features among 30 pediatric ALL patients.	56
Figure (4): Frequency of pretreatment hematological features among 30 pediatric ALL patients.	59
Figure (5): Frequency of immunophenotyping among 30 pediatric ALL patients.	61
Figure (6): Relation between immunophenotyping and risk Status.	63
Figure (7): Serum fibrinogen levels pre,during and after induction therapy with L-asparaginase in 30 pediatric ALL patients.	67
Figure (8): Hemostatic changes before, during and after asparaginase therapy.	68
Figure (9): Metabolic changes before, during and after asparaginase therapy.	72
Figure (10): Relation between TAT level and risk status according to immunophenotyping.	74
Figure (11): Clinical feature pre, during and after induction therapy.	79
Figure (12): Signs of coagulation toxicity according to WHO toxicity grading.	87

CONTENTS

- List of tables
- List of figures
- List of abbreviations
- Introduction and Aim Of The Work
.....1-2
- Review Of Literature.....3-43

Chapter I: Acute lymphoblastic leukemia

- *Epidemiology3
- *Pathogenesis4
- *Classification of ALL.....6
- *Diagnosis of ALL.....12
- *Prognostic factors.....19
- *Treatment of ALL.....26

ChapterII:L-asparaginase in the treatment of

- ALL27-43
- Patients and methods.....44-49
- Results.....50-87
- Discussion.....88-96
- Summary and Conclusion.....97-100
- References.....101-114
- Arabic summary

Conclusion and recommendations

*ALL induction therapy is a very critical period, with significant hemostatic & metabolic derangement.

*A significant increase in TAT complex was observed in the ALL patients especially in the high risk group.

*Since, increased TAT complex in plasma indicates in vivo thrombin generation so this complex seems to be a sensitive assay for early coagulation derangement in such patients.

*From these results, it is possible that hypercoagulability state exists in ALL patients during induction therapy.

*Significant hypertriglycemia & increased serum amylase level were detected during & persistent after ALL induction therapy.

*Hyperglycemia was detected during induction therapy and regular follow up of blood glucose level is mandatory during induction therapy with L- asparaginase.

*Large studies are needed to determine the incidence of coagulation & lipid abnormalities in long –term survivors of ALL as well as the relation between such abnormalities & other late effects of treatment, like cerebrovascular & cardiac complications.

Conclusion and recommendations

DISCUSSION

Acute lymphoblastic leukemia (ALL) is the most common malignancy of childhood ,representing nearly one third of all pediatric cancers. Chemotherapy treatment is associated with long list of side effects ,some common side effects are bone marrow suppression and immunosuppression.

L-asparaginase as a single agent chemotherapy has yielded complete remission rate of 60% and hence it is considered one of the important induction drugs in ALL treatment(Sahu,1998).

The present study aimed to study hemostatic and metabolic changes at time of diagnosis of ALL, during and after induction therapy ,and to find out any possible association between such changes ,clinical presentation ,hematological parameters and ALL risk status .

This study comprised 30 patients with acute lymphoblastic leukemia below the age of 18 years, who

DISCUSSION

presented to the Pediatric Oncology Clinic, Children's Hospital Ain Shams University and Tanta Cancer Center.

The median age of patients in the present study was 7 years with a mean of 7.35 ± 3.97 years and a peak age incidence of 5-10 years which is in agreement with (Reiter et al, 1994).

Regarding the sex distribution, there was obvious male predominance, male represents 61% of total patients with male : female ratio of 1.3: 1. This is in agreement with most series which reported a male: female ratio of 1.5:1 to 2.5:1 in ALL (Reiter et al, 1994, Margolin and Poplack, 1997).

Regarding FAB morphological classification L2 was the most common subtype in this study which represents 46.6% of the ALL patients. Similar findings were reported by (Pui et al, 2000). According to immunophenotyping the most frequent immunophenotyping encountered was the pre-B in 13 patients (43.3%) followed by C-ALLA in 10 patients (33.3%), T-cell in 6 patients (20%) then early B in one

DISCUSSION

patient (3.3%) ,which is in agreement with (Kamel et al, 1996) .

In the current study lymphadenopathy was found in 63% ,hepatomegaly in 14% and splenomegaly in 46% of the patients. These results are in concordance with the Egyptian study by kosary, et al, 1999.

We studied the effect of asparaginase on coagulation and metabolism during induction therapy and we found that there was a small subgroup of children with elevated prothrombotic marker before we started the treatment. TAT level was significantly elevated in (7/30) patients prior to start of chemotherapy which indicate the disease it self can cause thromboembolic complications , There was statistically significant increase in the mean level of TAT during induction therapy and after remission induction in comparison with pretreatment levels ($p_1=0.0$, $p_2=0.0$ respectively) this goes with that reported in other studies (Mieczyslaw, et al ;2000).

TAT in plasma reflects the amount of thrombin formed in the blood vessels and so an increase in this complex suggests the activation of the coagulation cascade in the blood stream (latent clotting activation)

DISCUSSION

From these results , it is possible that hypercoagulability or damage to vessel walls, which activates the coagulation cascade in these cases

Thromboembolic events (TE) are serious complications of childhood ALL treatment ,that results in significant morbidity and mortality . These events are strongly associated with the administration of L-asparaginase. There have been many studies reporting TE and assessing the coagulopathy associated with treatment (Priest et al ,1982).

Several authors (Inge, et al,2006) had studied the influence of asparaginase therapy on the coagulation state and had shown that the disease process itself causes an increase in procoagulant activity and endothelial injury, as well as decrease in natural coagulation inhibitors.

Albert, 1999, Matthias, et al, 2003 found that sparaginase as a single agent significantly decreases plasma concentrations of almost all coagulation proteins and inhibitors measured compared with plasma levels at presentation .Combination chemotherapy with asparaginase decrease plasma concentration of most